No Data
No Data
Cassava Alzheimer's Candidate Simufilam Clears Phase 3 Safety Review
Cassava Sciences' Alzheimer's Treatment Shows Promise: A Strong Buy Recommendation
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
The credibility of the clinical trial results for an experimental Alzheimer's drug has been called into question following a critical inspection report by the Food and Drug Administration (FDA).What H
Boeing, Oracle, Meta Platforms, Cassava Sciences, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Monday, the U.S. stock market presented a mixed performance. The Dow Jones index managed to turn higher, trading up by 0.12% to 38,769.66. However, the NASDAQ and the S&P 500 indices fell by 0.41%
Cassava Sciences Again Under Scrutiny Over Alzheimer's Drug Research
No Data